Within the DEKODE cohort, we demonstrate that DKA in individuals with type 2 diabetes treated with SGLT2 inhibitors is characterised by a distinct biochemical profile with notably lower blood glucose levels and more pronounced acidosis compared to SGLT2i non‐users. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.